LAA closure (LAAC) is a proven alternative to oral anticoagulation for preventing stroke in patients with non-valvular AF. In the era of NOACs the clinical evidence is also emerging. Join the panelists to discuss the implications of current and future trials on clinical practice. A live case from the University Clinic Aarhus, Denmark will focus on intracardiac echocardiography (ICE) to guide the LAA closure procedure with the next generation device WATCHMAN FLX.
Prof Tim Betts, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, UK
Dr Caroline Kleinecke, Clinic Waldshut-Tiengen, Germany
Prof Ignacio Cruz Gonzalez, University Hospital of Salamanca, Spain
Prof Jens Erik Nielsen-Kudsk, Aarhus University, Aarhus, Denmark
Prof Henning Ebelt, Catholic Hospital 'St Johann Nepomuk', Erfurt, Germany
Prof Marek Grygier, Poznan University of Medical Sciences, Poznan, Poland
Discuss the emerging evidence for the LAA closure therapy in the era of NOACs
Follow a live case with WATCHMAN FLX guided by ICE imaging
Learn how new workstreams with ICE can reduce the need for General Anaesthesia
Understand the benefits of combined procedures (AF Ablation + LAA closure) for patients
Learn about the trial design and endpoints of the OPTION trial and discuss the implication on clinical practice.
Understand how the new implantation technique of WATCHMAN FLX can optimize procedural results
Interventional Cardiologists and Electrophysiologists who would like to learn more about the growing evidence for the LAA closure therapy with WATCHMAN FLX
Non-invasive Cardiologists with an interest in the clinical evidence and the implications for the LAA closure therapy